From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Dermatology>
  4. Summary and Comment

Isotretinoin and Inflammatory Bowel Disease Revisited

Isotretinoin therapy in the previous 12 months significantly raised the risk for ulcerative colitis but not for Crohn disease.

An association between isotretinoin use and inflammatory bowel disease (IBD) has been suggested. In November 2009, we covered a study by Bernstein and colleagues, which demonstrated no more than a chance association between isotretinoin use and any type of IBD, and a review by Crockett and colleagues, which concluded that a causal association between isotretinoin and IBD had yet to be established. To further evaluate a possible association, some authors of the latter review used a large U.S. database to perform a case-control study comparing isotretinoin use in 8189 patients with incident IBD and 21,832 controls matched for age, sex, and geographic region. The period assessed for pre-IBD diagnosis isotretinoin use was 12 months.

Of the IBD patients, 3664 had Crohn disease (CD), 4428 had ulcerative colitis (UC), and 97 had IBD that could not be classified. Sixty subjects had received isotretinoin (24 cases and 36 controls). Isotretinoin use was strongly associated with UC (odds ratio, 4.36) but not with CD. In addition, higher doses and longer durations of isotretinoin treatment increased the risk for UC. When the authors extended the period examined for previous isotretinoin use from 12 to 24 months, the association between isotretinoin and UC was weaker but still statistically significant. Methodological differences between this study and the Bernstein study may explain the differences in findings.

Comment: This study needs replication, but its results suggest that risk for UC might be increased in isotretinoin recipients. Therefore, we should warn patients of this rare but potentially real risk and, if bowel symptoms develop, consider stopping isotretinoin until the patient is examined and cleared by a gastroenterologist for further therapy.

Jeffrey P. Callen, MD

Published in Journal Watch Dermatology May 21, 2010

Citation(s):

Crockett SD et al. Isotretinoin use and the risk of inflammatory bowel disease: A case–control study. Am J Gastroenterol 2010 Mar 30; [e-pub ahead of print]. (http://dx.doi.org/10.1038/ajg.2010.124)

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2010. Massachusetts Medical Society. All rights reserved.